Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (525)	11/15/1999 12:32:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 626

RCM, Thanks for putting together what was discussed here at SI and at yahoo TTP board. I will add that InvestorMD early posts on yahoo board were very helpful to me. You mentioned several my posts and quote me as one who is hot on TTP. Ended, I was (for last two years) and am continue to be strong TTP supporter, based on Iloperidone promises. However, there is one thing that I mentioned early and will repeat again. Maybe someone, somehow have right answer for it. Slide 35: <<No difference in heart rate and blood pressure vs. other antipshyhotics>> This isn't entirely true. Because Ilo is potent adrenergic alpha-1 receptor antagonist (more potent than Zyprexa or risperidone), its cardiovascular side effects may be issue which will effects drug market opportunity. I do not have any data which may support or neutralize this my concern. I do not believe that cardiovacular side effects (if at all) will be big issue, but when CNS drug is on plate, one is never certain for sure. As you said, risk-reward ratio is on right side, as far as I am investor. Miljenko PS: TD, next time take glasses when you read SEC file. Also, leave hype at home.